Clinical Trial

VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations

Study acronym: VALIENT
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will test the hypothesis that vorasidenib in combination with lomustine will be safe and tolerable. The overall goal of this study is to identify the optimal vorasidenib dose that can be tested in a subsequent phase 2 study to determine the efficacy of vorasidenib in combination with lomustine in patients with recurrent IDH mutant gliomas.
Trial Details
NCT Number NCT07629089
Lead Sponsor Megan Mantica
Collaborators: Institut de Recherches Internationales Servier
Conditions Brain Cancer
Enrollment 24 participants
Start Date 2026-06-30
Primary Completion 2030-06-30 (estimated)
Study Completion 2035-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-05